Literature DB >> 27210548

A hingeless Fc fusion system for site-specific cleavage by IdeS.

Shabazz Novarra1, Luba Grinberg1, Keith W Rickert1, Arnita Barnes1, Susan Wilson1, Manuel Baca1.   

Abstract

Fusion of proteins to the Fc region of IgG is widely used to express cellular receptors and other extracellular proteins, but cleavage of the fusion partner is sometimes required for downstream applications. Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) is a protease with exquisite specificity for human IgG, and it can also cleave Fc-fusion proteins at a single site in the N-terminal region of the CH2 domain. However, the site of IdeS cleavage results in the disulfide-linked hinge region partitioning with the released protein, complicating downstream usage of the cleaved product. To tailor the Fc fragment for release of partner proteins by IdeS treatment, we investigated the effect of deleting regions of IgG-derived sequence that are upstream of the cleavage site. Elimination of the IgG-derived hinge sequence along with several residues of the CH2 domain had negligible effects on expression and purity of the fusion protein, while retaining efficient processing by IdeS. An optimal Fc fragment comprising residues 235-447 of the human IgG1 heavy chain sufficed for efficient production of fusion proteins and minimized the amount of residual Ig-derived sequence on the cleavage product following IdeS treatment. Pairing of this truncated Fc fragment with IdeS cleavage enables highly specific cleavage of Fc-fusion proteins, thus eliminating the need to engineer extraneous cleavage sequences. This system should be helpful for producing Fc-fusion proteins requiring downstream cleavage, particularly those that are sensitive to internal miscleavage if treated with alternative proteases.

Entities:  

Keywords:  Fc fusion; IdeS; fusion protein; site-specific cleavage

Mesh:

Substances:

Year:  2016        PMID: 27210548      PMCID: PMC4968090          DOI: 10.1080/19420862.2016.1186321

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  27 in total

1.  System for cleavable Fc fusion proteins using tobacco etch virus (TEV) protease.

Authors:  J Haspel; C Blanco; J Jacob; M Grumet
Journal:  Biotechniques       Date:  2001-01       Impact factor: 1.993

2.  Crystallographic structure studies of an IgG molecule and an Fc fragment.

Authors:  R Huber; J Deisenhofer; P M Colman; M Matsushima; W Palm
Journal:  Nature       Date:  1976-12-02       Impact factor: 49.962

Review 3.  Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.

Authors:  Chichi Huang
Journal:  Curr Opin Biotechnol       Date:  2009-11-04       Impact factor: 9.740

4.  Expression and ligand binding assays of soluble cytokine receptor-immunoglobulin fusion proteins.

Authors:  S J Brown; K A Becherer; K Blumeyer; C Kautzer; F Axelrod; H Le; S J McConnell; A Whalley; D G Spinella
Journal:  Protein Expr Purif       Date:  1998-10       Impact factor: 1.650

5.  The covalent structure of an entire gammaG immunoglobulin molecule.

Authors:  G M Edelman; B A Cunningham; W E Gall; P D Gottlieb; U Rutishauser; M J Waxdal
Journal:  Proc Natl Acad Sci U S A       Date:  1969-05       Impact factor: 11.205

6.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

7.  Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments.

Authors:  S M Chamow; D H Peers; R A Byrn; M G Mulkerrin; R J Harris; W C Wang; P J Bjorkman; D J Capon; A Ashkenazi
Journal:  Biochemistry       Date:  1990-10-23       Impact factor: 3.162

8.  Generation of soluble interleukin-1 receptor from an immunoadhesin by specific cleavage.

Authors:  J T Beck; S A Marsters; R J Harris; P Carter; A Ashkenazi; S M Chamow
Journal:  Mol Immunol       Date:  1994-12       Impact factor: 4.407

9.  Thermodynamic analysis of the activation mechanism of the GCSF receptor induced by ligand binding.

Authors:  Shouhei Mine; Takumi Koshiba; Eijiro Honjo; Tomoyuki Okamoto; Taro Tamada; Yoshitake Maeda; Yasuko Matsukura; Akane Horie; Matsujiro Ishibashi; Miharu Sato; Mizue Azuma; Masao Tokunaga; Katsutoshi Nitta; Ryota Kuroki
Journal:  Biochemistry       Date:  2004-03-09       Impact factor: 3.162

10.  Biological properties of a CD4 immunoadhesin.

Authors:  R A Byrn; J Mordenti; C Lucas; D Smith; S A Marsters; J S Johnson; P Cossum; S M Chamow; F M Wurm; T Gregory; J E Groopman; D J Capon
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

View more
  5 in total

1.  Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.

Authors:  Stefan Warmuth; Tea Gunde; Daniel Snell; Matthias Brock; Christopher Weinert; Alexandre Simonin; Christian Hess; Julia Tietz; Maria Johansson; Fabio Mario Spiga; Robin Heiz; Naomi Flückiger; Sandro Wagen; Julia Zeberer; Dania Diem; Dana Mahler; Belinda Wickihalder; Simone Muntwiler; Bithi Chatterjee; Benjamin Küttner; Bettina Bommer; Yasemin Yaman; Peter Lichtlen; David Urech
Journal:  Oncoimmunology       Date:  2021-12-02       Impact factor: 7.723

2.  Crystal structure of the human 4-1BB/4-1BBL complex.

Authors:  Ryan N Gilbreth; Vaheh Y Oganesyan; Hamza Amdouni; Shabazz Novarra; Luba Grinberg; Arnita Barnes; Manuel Baca
Journal:  J Biol Chem       Date:  2018-05-02       Impact factor: 5.157

3.  An antidote approach to reduce risk and broaden utility of antibody-based therapeutics.

Authors:  Alyse D Portnoff; Cuihua Gao; M Jack Borrok; Xizhe Gao; Changshou Gao; G Jonah Rainey
Journal:  J Biol Chem       Date:  2017-03-03       Impact factor: 5.157

4.  Impairment of IgG Fc functions promotes tumor progression and suppresses NK cell antitumor actions.

Authors:  Xuejun Fan; Zihao Yuan; Yueshui Zhao; Wei Xiong; Hao-Ching Hsiao; Rahmawati Pare; Jianmin Ding; Ahmad Almosa; Kai Sun; Songlin Zhang; Robert E Jordan; Cheok Song Lee; Zhiqiang An; Ningyan Zhang
Journal:  Commun Biol       Date:  2022-09-14

5.  Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.

Authors:  Tianhang Zhai; Chao Wang; Yifeng Xu; Weifeng Huang; Zhijun Yuan; Tao Wang; Shuang Dai; Shaogang Peng; Tuling Pang; Wenchao Jiang; Yuhua Huang; Yuefeng Zou; Yingda Xu; Joanne Sun; Xinjiang Gong; Jinping Zhang; Andy Tsun; Bin Li; Xiaoniu Miao
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.